Results 351 to 360 of about 303,514 (383)
Drugs, 2006 A fixed-dose pioglitazone/metformin tablet is approved in the US and the EU for the treatment of adult patients with type 2 diabetes mellitus who currently have inadequate glycaemic control with metformin monotherapy. In the US, the combination tablet is also approved for the treatment of adult patients with type 2 diabetes who currently have ...
Emma D. Deeks, Lesley J. Scott
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Endocrinology and Metabolism Clinics of North America, 1997
Metformin, a dimethylbiguanide, was first synthesized in 1929 and was shown to be a potent hypoglycemic agent. It was rediscovered in 1957 and was widely used in Europe to treat obese type II patients. Metformin resurfaced in the 1980s and was shown to increase insulin sensitivity; this has led to its introduction to clinical practice in the United ...
P M, Bell, D R, Hadden
openaire +2 more sources
Metformin, a dimethylbiguanide, was first synthesized in 1929 and was shown to be a potent hypoglycemic agent. It was rediscovered in 1957 and was widely used in Europe to treat obese type II patients. Metformin resurfaced in the 1980s and was shown to increase insulin sensitivity; this has led to its introduction to clinical practice in the United ...
P M, Bell, D R, Hadden
openaire +2 more sources
Current Diabetes Reviews, 2020
Introduction: The Diabetes Prevention Program study results indicated that metformin therapy was not as beneficial as a lifestyle modification for delaying the development of type 2 diabetes in individuals at high risk of the disease. A key feature in the etiology of type 2 diabetes mellitus, which appears in the prediabetic phase, is a significant ...
Dick J. Bekedam, Rob N.M. Weijers
openaire +2 more sources
Introduction: The Diabetes Prevention Program study results indicated that metformin therapy was not as beneficial as a lifestyle modification for delaying the development of type 2 diabetes in individuals at high risk of the disease. A key feature in the etiology of type 2 diabetes mellitus, which appears in the prediabetic phase, is a significant ...
Dick J. Bekedam, Rob N.M. Weijers
openaire +2 more sources
Annals of Internal Medicine, 2002 Metformin is an insulin-sensitizing agent with potent antihyperglycemic properties. Its efficacy in reducing hyperglycemia in type 2 diabetes mellitus is similar to that of sulfonylureas, thiazolidinediones, and insulin. Metformin-based combination therapy is often superior to therapy with a single hypoglycemic agent.
Dmitri Kirpichnikov +2 more
openaire +2 more sources
Tijdschrift voor praktijkondersteuning, 2014
Na de ontdekking en internationale introductie in 1923 van insuline voor de behandeling van diabetes mellitus, is in 1959 metformine internationaal in de handel gebracht als een van de eerste orale bloedglucoseverlagende middelen.
openaire +2 more sources
Na de ontdekking en internationale introductie in 1923 van insuline voor de behandeling van diabetes mellitus, is in 1959 metformine internationaal in de handel gebracht als een van de eerste orale bloedglucoseverlagende middelen.
openaire +2 more sources
Drugs of Today, 2008
Metformin is a well-established ingredient of diabetes management, both as a monotherapy in early stages of type 2 diabetes and as adjunct therapy to virtually every other antihyperglycemic medicine available today. Despite low potency and a long list of contraindications, metformin has remained successful and even expanded experimental use due to its ...
openaire +2 more sources
Metformin is a well-established ingredient of diabetes management, both as a monotherapy in early stages of type 2 diabetes and as adjunct therapy to virtually every other antihyperglycemic medicine available today. Despite low potency and a long list of contraindications, metformin has remained successful and even expanded experimental use due to its ...
openaire +2 more sources
Regulatory Toxicology and Pharmacology, 2018
This review investigates the different biological effect of Metformin (MET) in different conditions. MET is an oral antidiabetic drug used for the treatment of type 2 diabetes mellitus (T2DM) particularly in overweight people. The main mechanism of action of the MET is inhibition of hepatic glucose production and reduction of insulin resistance.
Tuğba Adak +3 more
openaire +3 more sources
This review investigates the different biological effect of Metformin (MET) in different conditions. MET is an oral antidiabetic drug used for the treatment of type 2 diabetes mellitus (T2DM) particularly in overweight people. The main mechanism of action of the MET is inhibition of hepatic glucose production and reduction of insulin resistance.
Tuğba Adak +3 more
openaire +3 more sources
Diabetes Research and Clinical Practice, 2018
Metformin is a lipophilic biguanide which inhibits hepatic gluconeogenesis and improves peripheral utilization of glucose. It is the first line pharmacotherapy for glucose control in patients with Type 2 diabetes due to its safety, efficacy and tolerability.
Tahseen A Chowdhury, Ritwika Mallik
openaire +3 more sources
Metformin is a lipophilic biguanide which inhibits hepatic gluconeogenesis and improves peripheral utilization of glucose. It is the first line pharmacotherapy for glucose control in patients with Type 2 diabetes due to its safety, efficacy and tolerability.
Tahseen A Chowdhury, Ritwika Mallik
openaire +3 more sources
General Pharmacology: The Vascular System, 1993
Metformin (dimethylbiguanide) is an antihyperglycaemic drug used to treat non-insulin dependent diabetes mellitus. It acts in the presence of insulin to increase glucose utilization and reduce glucose production, thereby countering insulin resistance.
openaire +3 more sources
Metformin (dimethylbiguanide) is an antihyperglycaemic drug used to treat non-insulin dependent diabetes mellitus. It acts in the presence of insulin to increase glucose utilization and reduce glucose production, thereby countering insulin resistance.
openaire +3 more sources
Rejuvenation Research, 2011
Abstract Geroprotectors are drugs that decrease the rate of aging and therefore extend life span. Metformin has been described as a geroprotector, and several studies have shown that metformin can slow down the rate of aging. The mechanisms behind the geroprotective effect of metformin are less established.
openaire +3 more sources
Abstract Geroprotectors are drugs that decrease the rate of aging and therefore extend life span. Metformin has been described as a geroprotector, and several studies have shown that metformin can slow down the rate of aging. The mechanisms behind the geroprotective effect of metformin are less established.
openaire +3 more sources